Intellia Therapeutics, Inc. (NTLA) · Insider trading
What Intellia Therapeutics's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$1.40M
1 insider, 1 trade
Sold, 12 months
$2.16M
7 insiders, 56% under a plan
Net, 12 months
−$760,814
bought less sold
Latest filing
2026-10-06
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Leonard John MDirector, President and CEO | – | $1.76M | 7 | 2026-08-21 | 1,147,064 |
| Cohen Fred EDirector | $1.40M | – | 1 | 2026-01-05 | 207,453 |
| Chase William JDirector | $1.00M | – | 1 | 2025-08-20 | 134,693 |
| Dulac Edward J IIIEVP, Chief Financial Officer | – | $338,803 | 4 | 2026-07-22 | 148,175 |
| Lebwohl DavidEVP, Chief Medical Officer | – | $226,031 | 2 | 2026-01-05 | 121,249 |
| Basta JamesEVP, General Counsel | – | $221,728 | 4 | 2026-03-02 | 156,794 |
| Clark ElianaEVP, Chief Technical Officer | – | $209,226 | 6 | 2026-03-02 | 93,864 |
| Dube Michael PVP, Chief Accounting Officer | – | $169,148 | 6 | 2026-10-02 | 65,022 |
| Sepp-Lorenzino LauraEVP, Chief Scientific Officer | – | $109,206 | 1 | 2025-01-03 | 77,388 |
| Hicks DerekEVP, Chief Business Officer | – | $79,194 | 1 | 2025-01-03 | 59,878 |
| Schultes Birgit CEVP, Chief Scientific Officer | – | $78,897 | 2 | 2026-01-05 | 98,533 |
| Goodman JesseDirector | – | $29,068 | 2 | 2025-07-01 | 24,359 |
| Bhanji MunaDirector | – | $4,895 | 2 | 2025-04-29 | 19,203 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Dube Michael PVP, Chief Accounting Officer | Sale | 1,864 | 12.43 | $23,170 | 65,022 | Form 4 |
| 2026-08-21 | Leonard John MDirector, President and CEO | Saleplan | 2,785 | 13.00 | $36,205 | 1,147,064 | Form 4 |
| 2026-08-20 | Leonard John MDirector, President and CEO | Saleplan | 19,890 | 12.60 | $250,614 | 1,149,849 | Form 4 |
| 2026-07-22 | Dulac Edward J IIIEVP, Chief Financial Officer | Sale | 8,111 | 11.25 | $91,249 | 148,175 | Form 4 |
| 2026-07-02 | Dulac Edward J IIIEVP, Chief Financial Officer | Saleplan | 4,677 | 18.00 | $84,186 | 156,286 | Form 4 |
| 2026-07-01 | Dube Michael PVP, Chief Accounting Officer | Sale | 2,641 | 16.78 | $44,316 | 66,886 | Form 4 |
| 2026-03-02 | Clark ElianaEVP, Chief Technical Officer | Sale | 607 | 13.78 | $8,364 | 93,864 | Form 4 |
| 2026-03-02 | Basta JamesEVP, General Counsel | Sale | 1,211 | 13.78 | $16,688 | 156,794 | Form 4 |
| 2026-01-05 | Dube Michael PVP, Chief Accounting Officer | Sale | 2,989 | 9.21 | $27,529 | 52,277 | Form 4 |
| 2026-01-05 | Dulac Edward J IIIEVP, Chief Financial Officer | Sale | 6,379 | 9.21 | $58,751 | 99,683 | Form 4 |
| 2026-01-05 | Clark ElianaEVP, Chief Technical Officer | Sale | 9,515 | 9.21 | $87,633 | 87,118 | Form 4 |
| 2026-01-05 | Lebwohl DavidEVP, Chief Medical Officer | Sale | 11,903 | 9.21 | $109,627 | 121,249 | Form 4 |
| 2026-01-05 | Cohen Fred EDirector | Buy | 150,000 | 9.35 | $1.40M | 207,453 | Form 4 |
| 2026-01-05 | Basta JamesEVP, General Counsel | Sale | 10,397 | 9.21 | $95,756 | 101,528 | Form 4 |
| 2026-01-05 | Schultes Birgit CEVP, Chief Scientific Officer | Sale | 8,508 | 9.21 | $78,359 | 98,533 | Form 4 |
| 2026-01-05 | Leonard John MDirector, President and CEO | Sale | 34,146 | 9.21 | $314,485 | 1,013,339 | Form 4 |
| 2025-12-11 | Leonard John MDirector, President and CEO | Saleplan | 49,959 | 9.49 | $474,111 | 1,077,115 | Form 4 |
| 2025-12-11 | Leonard John MDirector, President and CEO | Saleplan | 32,832 | 9.47 | $310,919 | 1,044,283 | Form 4 |
| 2025-12-11 | Leonard John MDirector, President and CEO | Saleplan | 5,355 | 9.59 | $51,354 | 1,038,928 | Form 4 |
| 2025-10-01 | Dube Michael PVP, Chief Accounting Officer | Sale | 1,871 | 17.38 | $32,518 | 55,266 | Form 4 |
| 2025-10-01 | Schultes Birgit CEVP, Chief Scientific Officer | Sale | 31 | 17.38 | $539 | 105,184 | Form 4 |
| 2025-08-20 | Chase William JDirector | Buy | 100,000 | 10.03 | $1.00M | 134,693 | Form 4 |
| 2025-07-23 | Dulac Edward J IIIEVP, Chief Financial Officer | Sale | 7,462 | 14.02 | $104,617 | 106,062 | Form 4 |
| 2025-07-02 | Dube Michael PVP, Chief Accounting Officer | Sale | 2,503 | 9.95 | $24,905 | 57,137 | Form 4 |
| 2025-07-01 | Clark ElianaEVP, Chief Technical Officer | Sale | 1,022 | 9.82 | $10,036 | 95,369 | Form 4 |
| 2025-07-01 | Goodman JesseDirector | Saleplan | 1,547 | 9.23 | $14,279 | 24,359 | Form 4 |
| 2025-06-30 | Goodman JesseDirector | Saleplan | 1,547 | 9.56 | $14,789 | 25,906 | Form 4 |
| 2025-04-29 | Bhanji MunaDirector | Saleplan | 265 | 8.50 | $2,252 | 19,203 | Form 4 |
| 2025-03-04 | Basta JamesEVP, General Counsel | Sale | 2,572 | 8.99 | $23,122 | 111,925 | Form 4 |
| 2025-03-04 | Clark ElianaEVP, Chief Technical Officer | Sale | 679 | 8.99 | $6,104 | 95,369 | Form 4 |
| 2025-01-29 | Bhanji MunaDirector | Saleplan | 265 | 9.97 | $2,642 | 19,468 | Form 4 |
| 2025-01-03 | Sepp-Lorenzino LauraEVP, Chief Scientific Officer | Sale | 8,966 | 12.18 | $109,206 | 77,388 | Form 4 |
| 2025-01-03 | Leonard John MDirector, President and CEO | Sale | 26,807 | 12.18 | $326,509 | 941,115 | Form 4 |
| 2025-01-03 | Hicks DerekEVP, Chief Business Officer | Sale | 6,502 | 12.18 | $79,194 | 59,878 | Form 4 |
| 2025-01-03 | Lebwohl DavidEVP, Chief Medical Officer | Sale | 9,557 | 12.18 | $116,404 | 87,666 | Form 4 |
| 2025-01-03 | Basta JamesEVP, General Counsel | Sale | 7,074 | 12.18 | $86,161 | 74,497 | Form 4 |
| 2025-01-03 | Dube Michael PVP, Chief Accounting Officer | Sale | 1,372 | 12.18 | $16,711 | 45,640 | Form 4 |
| 2025-01-03 | Clark ElianaEVP, Chief Technical Officer | Sale | 7,422 | 12.18 | $90,400 | 64,048 | Form 4 |
| 2025-01-02 | Clark ElianaEVP, Chief Technical Officer | Sale | 556 | 12.03 | $6,689 | 71,470 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
28 × grant or award5 × option exercise
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-09 | Bhanji MunaDirector | Grant or award A | +9,200 | – | 36,403 | Form 4 |
| 2026-06-09 | Cohen Fred EDirector | Grant or award A | +9,200 | – | 216,653 | Form 4 |
| 2026-06-09 | Goff BrianDirector | Grant or award A | +9,200 | – | 32,609 | Form 4 |
| 2026-06-09 | Keresty GeorgiaDirector | Grant or award A | +9,200 | – | 41,083 | Form 4 |
| 2026-06-09 | Verwiel FrankDirector | Grant or award A | +9,200 | – | 35,148 | Form 4 |
| 2026-06-09 | Chase William JDirector | Grant or award A | +9,200 | – | 143,893 | Form 4 |
| 2026-06-09 | Goodman JesseDirector | Grant or award A | +9,200 | – | 33,559 | Form 4 |
| 2026-03-01 | Dube Michael PVP, Chief Accounting Officer | Grant or award A | +17,250 | – | 69,527 | Form 4 |
| 2026-03-01 | Clark ElianaEVP, Chief Technical Officer | Grant or award A | +7,353 | – | 94,471 | Form 4 |
| 2026-03-01 | Schultes Birgit CEVP, Chief Scientific Officer | Grant or award A | +39,200 | – | 137,733 | Form 4 |
| 2026-03-01 | Dulac Edward J IIIEVP, Chief Financial Officer | Grant or award A | +61,280 | – | 160,963 | Form 4 |
| 2026-03-01 | Lebwohl DavidEVP, Chief Medical Officer | Grant or award A | +9,943 | – | 131,192 | Form 4 |
| 2026-03-01 | Basta JamesEVP, General Counsel | Grant or award A | +46,080 | – | 158,005 | Form 4 |
| 2026-03-01 | Leonard John MDirector, President and CEO | Grant or award A | +156,400 | – | 1,169,739 | Form 4 |
| 2025-12-12 | Leonard John MDirector, President and CEO | Option exercise M | +8,557 | 6.83 | 1,047,485 | Form 4 |
| 2025-12-11 | Leonard John MDirector, President and CEO | Option exercise M | +49,959 | 6.83 | 1,127,074 | Form 4 |
| 2025-06-11 | Keresty GeorgiaDirector | Grant or award A | +8,000 | – | 31,883 | Form 4 |
| 2025-06-11 | Cohen Fred EDirector | Grant or award A | +8,000 | – | 57,453 | Form 4 |
| 2025-06-11 | Chase William JDirector | Grant or award A | +8,000 | – | 34,693 | Form 4 |
| 2025-06-11 | Bhanji MunaDirector | Grant or award A | +8,000 | – | 27,203 | Form 4 |
| 2025-06-11 | Goff BrianDirector | Grant or award A | +8,000 | – | 23,409 | Form 4 |
| 2025-06-11 | Goodman JesseDirector | Grant or award A | +8,000 | – | 27,453 | Form 4 |
| 2025-06-11 | Verwiel FrankDirector | Grant or award A | +8,000 | – | 25,948 | Form 4 |
| 2025-03-01 | Basta JamesEVP, General Counsel | Grant or award A | +40,000 | – | 114,497 | Form 4 |
| 2025-03-01 | Schultes Birgit CEVP, Chief Scientific Officer | Grant or award A | +37,600 | – | 105,215 | Form 4 |
| 2025-03-01 | Lebwohl DavidEVP, Chief Medical Officer | Grant or award A | +43,200 | – | 130,866 | Form 4 |
| 2025-03-01 | Dube Michael PVP, Chief Accounting Officer | Grant or award A | +14,000 | – | 59,640 | Form 4 |
| 2025-03-01 | Dulac Edward J IIIEVP, Chief Financial Officer | Grant or award A | +47,200 | – | 113,524 | Form 4 |
| 2025-03-01 | Leonard John MDirector, President and CEO | Grant or award A | +136,000 | – | 1,077,115 | Form 4 |
| 2025-03-01 | Clark ElianaEVP, Chief Technical Officer | Grant or award A | +32,000 | – | 96,048 | Form 4 |
| 2025-01-01 | Sepp-Lorenzino LauraEVP, Chief Scientific Officer | Option exercise M | +3,500 | – | 86,354 | Form 4 |
| 2025-01-01 | Leonard John MDirector, President and CEO | Option exercise M | +7,850 | – | 967,922 | Form 4 |
| 2025-01-01 | Lebwohl DavidEVP, Chief Medical Officer | Option exercise M | +3,189 | – | 97,223 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.